What changed from existing technology?
This study shows that modifying RNA in a special way can make gene editing work better in living animals, especially in the liver, with just one injection.
This study introduces densely modified RNA motifs in guide RNAs for prime editing, which enhances editing efficiency and enables in vivo application with a single injection.
Commercialization signals visible at publication
This is not a success probability or investment opinion. It prioritizes follow-up using evidence available when the paper was published.
Verified evidence · 0
- 시제품·장치 구현 근거 미확인
- 제조·규모 확장 근거 미확인
- 장기·실사용 검증 근거 미확인
Later patent, company, clinical, and production events are added separately only after verification.
Patent check: Not checked yetCurrent technology stage: Validation stage
See what changed before reading the full paper.
What still needs to be solved?
Repeated real-world validation, manufacturability, cost, and long-term stability still require follow-up evidence.
What could change if this succeeds?
The developed pegRNAs could be used for efficient in vivo gene editing applications, particularly in the liver, with potential for clinical translation using a single injection method.
Keep following this technology
Revisit changes when new papers, patents, company participation, validation, or products appear.